Merz Pharmaceuticals’ Positive Clinical Trials Results For NT-201

Merz Pharmaceuticals has announced results from two randomized, active controlled clinical trials in patients with blepharospasm and cervical dystonia. The results were presented at the Movement Disorder Society (MDS) 13th annual International Congress in Paris.

NT-201 is a neurotoxin therapy free from complexing proteins due to a combination of high biologic activity with low bacterial protein load. It has been approved for marketing in Europe since 2007 to treat various movement disorders. Recently it got approval in Canada for the indications of symptomatic management of blepharospasm, cervical dystonia and post-stroke spasticity of the upper limb.

Eric Pappert, Vice President of Medical Affairs at Merz Pharmaceuticals, said: The results of these studies reaffirm our beliefs that NT-201 (Xeomin botulinum neurotoxin free from complexing proteins) can be used to potentially aid focal dystonia and post-stroke spasticity sufferers.

In addition, NT-201 showed results in treating upper limb spasticity sufferers of various etiologies including stroke, brain injury, spinal cord injury, multiple sclerosis or cerebral palsy, warranting additional studies as a potential treatment option for a wide scope of patients.